The cobas® EBV test provides reliable, standardized, high-quality results for the improved management of transplant patients at risk of infection. The test is used by healthcare professionals in conjunction with with clinical signs and symptoms and relevant laboratory findings to assess if transplant patients are at risk of developing disease caused by EBV. The test is for use on the automated cobas® 5800/6800/8800 Systems.
Features and benefits of the cobas® EBV test
- Standardization – Results traceable to the WHO International Standard and reporting in IU/mL for improved harmonization in testing results across hospitals and institutions
- State-of-the-art design – Best-in-class test design with dual target assay design to provide reliable and reproducible results for reassurance in clinical decision making
- Efficiency, flexibility and simplicity – Ability to perform critical transplant testing (CMV, EBV, BKV) from a single sample on the cobas® 5800/6800/8800 Systems with an industry-leading menu, absolute automation and proven performance.
EBV could cause transplant-transmitted infections in immunocompromised transplant patients and is associated with a range of cancers, such as post-transplant lymphoproliferative disorder (PTLD).1 Early intervention with best-in-class monitoring tools provides actionable results which enable informed treatment decisions.